ACRV insider tax withholding: 99 shares, 4,122 shares remaining

Rhea-AI Filing Summary

Acrivon Therapeutics, Inc. (ACRV) reported an administrative insider transaction by its Chief Accounting Officer. On 11/14/2025, 99 shares of common stock were withheld by the company at a price of $2.24 per share to cover mandatory tax withholding upon the vesting of restricted stock units. After this tax-related share withholding, the officer beneficially owned 4,122 shares of Acrivon common stock directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Peterson Katharine

Role Chief Accounting Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	99	$2.24	$221.76

Holdings After Transaction: Common Stock — 4,122 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Peterson Katharine

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/14/2025		F(1)		99	D	$2.24	4,122	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

	/s/ Adam D. Levy, Attorney-in-Fact	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Acrivon Therapeutics (ACRV) report in this Form 4?

The filing reports that the Chief Accounting Officer had 99 shares of common stock withheld on 11/14/2025 to satisfy mandatory tax withholding upon the vesting of restricted stock units.

Who is the reporting person in the Acrivon Therapeutics (ACRV) Form 4?

The reporting person is an officer of Acrivon Therapeutics, serving as Chief Accounting Officer, and is filing as a single reporting person.

How many Acrivon Therapeutics (ACRV) shares does the officer own after the transaction?

Following the tax withholding transaction, the officer beneficially owned 4,122 shares of Acrivon Therapeutics common stock directly.

What was the purpose of the 99 Acrivon Therapeutics (ACRV) shares withheld?

According to the explanation of responses, the 99 shares were withheld by the issuer to satisfy the mandatory tax withholding requirement upon the vesting of restricted stock units.

What transaction code is used in the Acrivon Therapeutics (ACRV) Form 4?

The non-derivative transaction uses code "F", which indicates a transaction where shares are withheld to pay taxes in connection with the vesting of equity awards.

Does the Acrivon Therapeutics (ACRV) Form 4 report any derivative securities?

The filing includes a section for derivative securities, but no derivative transactions are reported in the provided table excerpt.